Ulas, A. Et Al. 2015. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?. Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.20 , 714-22.

Ulas, A., Avci, N., Kos, T., Cubukcu, E., Olmez, O. F., Bulut, N., ... Degirmenci, M.(2015). Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?. Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.20, 714-22.

Ulas, Arife Et Al. "Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?," Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.20, 714-22, 2015

Ulas, Arife Et Al. "Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?." Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.20, pp.714-22, 2015

Ulas, A. Et Al. (2015) . "Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?." Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.20, pp.714-22.

@article{article, author={Arife Ulas Et Al. }, title={Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?}, journal={Journal of B.U.ON. : official journal of the Balkan Union of Oncology}, year=2015, pages={714-22} }